Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Metformin XR in Grade 1 Obesity
NCT03710460Phase 4Unknown
- Sponsor
- Universidad de Guadalajara
- Start
- Jul 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Dapagliflozin, Metformin XR and Dapagliflozin + Metformin XR (3 arms). Primary endpoints: Body Weight at 12 weeks, Body Mass Index at 12 weeks and 6 more. Status: unknown.
02
Drugs
dapagliflozinmetformin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03710460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710460.